Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

NCT05298813 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
162
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Immune Biosolutions Inc